Maiwald Magazine

Press Coverage

5 Dec 2025 - Press Coverage

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement.

Royalty Pharma and Denali have entered into a $275 million financing agreement which, pursuant to a synthetic royalty agreement, is based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicle™-enabled enzyme rep...

25 Aug 2025 - Press Coverage

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma has acquired a royalty interest in Amgen's Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltr...

14 Jul 2025 - Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

Maiwald in the press

Publications

3 Jul 2026 - Publication

Shedding Light on the Black Box — AI Inventions under the Scrutiny of Art. 83 EPC, Managing IP 2026

The article examines the disclosure requirements for AI inventions under Article 83 EPC. Drawing on six decisions of the Boards of Appeal of the European Patent Office, it dem...

26 May 2026 - Publication

Podcast INSIGHT epi: The New Transparency Rules for Clinical Trials in the EU: Navigating Regulatory Disclosure and Patentability at the EPO and UPC

New INSIGHT epi podcast episode with Maiwald experts on clinical trial transparency and patentability In ...

29 Apr 2026 - Publication

Mobile foot measurement’s IP battle highlights easily overlooked step in startup journey, Managing IP, 2026

In an article for Managing IP, Dr Christian Meyer of Maiwald, in collaboration with Footprint Technologies, explains how a single process patent has had a significant impact o...

All publications

Events

Mon.

21 Sep 2026 |Upcoming

Maiwald at the 10th Munich IP Forum

On 21–22 September 2026, the Munich IP Forum will once again bring together leading representatives from industry, private practice, the judiciary, and the patent profession in Munich. The event provides a platform for exchanging insights on the latest developments in European patent law, with a particular focus on the Unified Patent Cou...

Thu.

2 Jul 2026 |Past Event|Reports

INTA Seminar for Paralegals 2026 in Munich

On Thursday, 2 July 2026, the International Trademark Association (INTA) will host the 2026 Seminar for Paralegals in Munich – a full‑day, German‑language programme specifically tailored to paralegals working in the fields of trademarks and brand protection. The event will take place from 9:00 am to 4:00 pm at the ...

Wed.

24 Jun 2026 |Past Event|Reports

ORIGINAL VS. IMITATION – Expert Forum on the 50th Plagiarius Awards

To mark the 50th anniversary of the “Plagiarius” negative award, Aktion Plagiarius e.V. and Maiwald are hosting a high‑level expert forum dedicated to the protection of intellectual property. The event will focus on strategies for protecting trademarks, designs and patents before national and international bodies, ...

Tue.

2 Jun 2026 |Past Event|Reports

Joint symposium with Oblon in Tokyo | 2 June 2026

Oblon and Maiwald are pleased to invite you to a complimentary joint international symposium on: U.S. and European patent practice: Important Aspects for Practitioners. Date and venue: Tuesday, 2 June 2026, 13:00 JST, at the AP Marunouchi, Tokyo

All events

News and Releases

Maiwald Blog

Shedding Light on the Black Box — AI Inventions under the Scrutiny of Art. 83 EPC

File Late, Pay Licence

Analysis of Examination Standards and Case Law for AI and Software-Related Inventions

Press Coverage

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement.

Royalty Pharma acquires licence interest for Amgen’s Imdelltra – Maiwald advises on transaction

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Staff News

Maiwald appoints Dr. Kerstin Wolff as Partner

Maiwald appoints Martina Boidol, Dr. Anja Fux, and Sebastian Herzog as managing partners

Dr Iris Müller and Dr Gabriel Kiefl sworn in as German patent attorneys

Publications

Shedding Light on the Black Box — AI Inventions under the Scrutiny of Art. 83 EPC, Managing IP 2026

Podcast INSIGHT epi: The New Transparency Rules for Clinical Trials in the EU: Navigating Regulatory Disclosure and Patentability at the EPO and UPC

Mobile foot measurement’s IP battle highlights easily overlooked step in startup journey, Managing IP, 2026

Awards

Managing IP honours Maiwald practitioners in the 2026 IP STARS, Rising Stars and Notable Practitioners rankings

IP STARS 2026: Maiwald once again among the leading IP firms

Handelsblatt Best Lawyers: Germany’s Best Lawyers 2026

Events

Maiwald at the 10th Munich IP Forum

INTA Seminar for Paralegals 2026 in Munich

ORIGINAL VS. IMITATION – Expert Forum on the 50th Plagiarius Awards

Joint symposium with Oblon in Tokyo | 2 June 2026